Mark L. Chiu - Publications, H-index & Citations

Mark L. Chiu

tavotek biotherapeutics inc.

36H指数

134论文数

6.2K被引数

收录论文 47

发表时间

CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy 靶向CDCP1的抗体药物偶联物和免疫细胞因子用于癌症治疗

Cancer Chemotherapy and Pharmacology

IF2.3

2026-08-17

PREAI

Guangmao Mu; Mingcan Yu; Fulai Zhou; Honglei Bi; Zhengxia Zha; Sheng Huang; Ying Jin; Chao Han; Mark L. Chiu; Di Zhang

A novel insulin-like growth factor II-based masking domain for conditional activation of therapeutic antibodies 一种基于胰岛素样生长因子II的新型掩蔽结构域，用于治疗性抗体的条件激活

mAbs

IF7.3

2026-05-06

OAAI

Lihua Shi; Minseon Cho; Motohiko Nishida; Mark L. Chiu; Di Zhang

Effect of ADCC-enhancing mutations on N-glycan profiles of human IgG1 antibodies ADCC增强突变对人类IgG1抗体N-糖基化谱的影响

Biochemical Journal

IF4.3

2026-05-01

PREAI

Han, Lu; Jiang, Hao; Chiu, Mark L.

A Tri-specific EGFR/cMet/VEGF Antibody Demonstrates Potent Multi-Mechanistic Activity in Preclinical Triple-Negative Breast Cancer Models 一种三特异性EGFR/cMet/VEGF抗体在临床前三阴性乳腺癌模型中显示出强大的多机制活性

Journal of Biological Chemistry

IF3.9

2026-04-30

OAAI

Pu Pu; Ying Jin; Songling Zhang; Yuqiang Xu; Peng Chen; Zhou Fulai; Sun Ping; Hao Jiang; Sheng Huang; Limin Chen; Meixia Fu; ZhengXia Zha; Maria P. MacWilliams; Mark L. Chiu

Engineering tandem VHHs to target different epitopes to enhance antibody-dependent cell-mediated cytotoxicity 工程化串联VHHs以靶向不同表位，增强抗体依赖性细胞介导的细胞毒性

FEBS OPEN BIO

IF2.3

2025-11-01

OAAI

Xu, Yuqiang; Jiang, Hao; Chen, Limin; Zhou, Fulai; Jin, Ying; Chiu, Mark L.

Targeted Hyaluronan Degradation Enhanced Tumor Growth Inhibition in Gastrointestinal Cancer Models 靶向透明质酸降解增强了胃肠道癌模型中的肿瘤生长抑制作用

Cancers 2025, Vol. 17, Page 3411

IF0

2025-10-23

OAAI

Fulai Zhou; Guangmao Mu; Honglei Bi; Limin Chen; Zhengxia Zha; Ying Jin; Mark L. Chiu

A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models 一种靶向EGFR/cMET/VEGF-A的三特异性抗体，显示出多种作用机制以抑制野生型和突变型NSCLC动物模型。

FRONTIERS IN ONCOLOGY

IF3.3

2025-05-16

OAAI

Jin, Ying; Sun, Ping; Chen, Peng; Xu, Yuqiang; Mu, Guangmao; Zha, Zhengxia; Wu, Simin; Fu, Meixia; Jiang, Hao; Huang, Sheng; Zhou, Fulai; Han, Chao; Chiu, Mark L.

Discovery and Phase 1 study of a novel monoclonal antibody against human IL-1β for the treatment of IL-1β-mediated diseases

CLINICAL AND EXPERIMENTAL IMMUNOLOGY

IF3.8

2025-02-18

PREAI

Cho, Minseon; Tam, Susan H.; Shi, Lihua; Fung, Isa; Tornetta, Mark; Canziani, Gabriela A.; Fung, Man-Cheong; Chiu, Mark L.; Han, Chao; Zhang, Di

Developing transcriptomic biomarkers for TAVO412 utilizing next generation sequencing analyses of preclinical tumor models

FRONTIERS IN IMMUNOLOGY

IF5.9

2025-02-10

OAAI

Jin, Ying; Chen, Peng; Zhou, Huajun; Mu, Guangmao; Wu, Simin; Zha, Zhengxia; Ma, Bin; Han, Chao; Chiu, Mark L.

A novel monoclonal antibody against human thymic stromal lymphopoietin for the treatment of TSLP-mediated diseases

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-12-11

OAAI

Shi, Lihua; Yu, Mingcan; Jin, Ying; Chen, Peng; Mu, Guangmao; Tam, Susan H.; Cho, Minseon; Tornetta, Mark; Han, Chao; Fung, Man-Cheong; Chiu, Mark L.; Zhang, Di

UNO-A001 (A001), a clinical candidate CD38 x CD3 bispecific with a novel structure, potently kills multiple myeloma cells in vitro and is highly effective in vivo

CANCER RESEARCH

IF16.6

2024-03-22

PREAI

Anderson, Mark; Ling, Yan; Chiu, Mark L.; Cheung, Peter

Multi-specific cMet x EGFR x VEGF antibody for difficult to treat cancers

CANCER RESEARCH

IF16.6

2023-04-04

PREAI

Chiu, Mark

TAVO412-A Novel Trispecific cMet x EGFR x VEGF Antibody for Triple Negative Breast Cancer

CANCER RESEARCH

IF16.6

2023-03-01

PREAI

Chiu, Mark

GFR Estimation in Potential Living Kidney Donors: Race- and Nonrace-based Equations and Measured GFR

KIDNEY MEDICINE

IF3.4

2022-12-01

OAAI

Goodson, David Alex; Chalupsky, Megan Rose; Wiegley, Nasim; Huang, Yihung; Chiu, Mark; Bang, Heejung; Roshanravan, Baback; Young, Brian Yim; Chen, Ling-Xin

A stable, engineered TL1A ligand co-stimulates T cells via specific binding to DR3

SCIENTIFIC REPORTS

IF3.9

2022-11-29

OAAI

Zwolak, Adam; Chan, Szeman Ruby; Harvilla, Paul; Mahady, Sally; Armstrong, Anthony A.; Luistro, Leopoldo; Tamot, Ninkka; Yamada, Douglas; Derebe, Mehabaw; Pomerantz, Steven; Chiu, Mark; Ganesan, Rajkumar; Chowdhury, Partha

Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET amivantamab (JNJ-61186372) 的发现，一种靶向EGFR和MET的双特异性抗体

JOURNAL OF BIOLOGICAL CHEMISTRY

IF3.9

2021-01-01

112

OAAI

Neijssen, Joost; Cardoso, Rosa M. F.; Chevalier, Kristen M.; Wiegman, Luus; Valerius, Thomas; Anderson, G. Mark; Moores, Sheri L.; Schuurman, Janine; Parren, Paul W. H., I; Strohl, William R.; Chiu, Mark L.

Design and characterization of novel dual Fc antibody with enhanced avidity for Fc receptors

PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS

IF2.8

2019-11-20

OAAI

Goulet, Dennis R.; Zwolak, Adam; Williams, James A.; Chiu, Mark L.; Atkins, William M.

Influence of the bispecific antibody IgG subclass on T cell redirection 双特异性抗体IgG亚类对T细胞重定向的影响

MABS

IF7.3

2019-06-26

OAAI

Kapelski, Stephanie; Cleiren, Erna; Attar, Ricardo M.; Philippar, Ulrike; Hasler, Julien; Chiu, Mark L.

Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors 人IgG亚类对小鼠和食蟹猴fc γ 受体的跨物种反应性

IMMUNOLOGY LETTERS

IF2.8

2018-05-01

PREAI

Derebe, Mehabaw G.; Nanjunda, Rupesh K.; Gilliland, Gary L.; Lacy, Eilyn R.; Chiu, Mark L.

Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody

MOLECULAR METABOLISM

IF6.6

2018-04-01

OAAI

Hinke, Simon A.; Cieniewicz, Anne M.; Kirchner, Thomas; D'Aquino, Katharine; Nanjunda, Rupesh; Aligo, Jason; Perkinson, Robert; Cooper, Philip; Boayke, Ken; Chiu, Mark L.; Jarantow, Steve; Lacy, Eilyn R.; Liang, Yin; Johnson, Dana L.; Whaley, Jean M.; Lingham, Russell B.; Kihm, Anthony J.

研究方向